Nephros, Inc. — FY2022 Form 10-K
Reporting period: Fiscal year ended December 31, 2022; filed March 23, 2023. Nephros develops and sells water filtration products for medical and commercial markets. Continuing revenue came entirely from Water Filtration; Renal Products generated no revenue. The former Pathogen Detection Systems (PDS) business is reported as discontinued operations.
Financial performance and liquidity
| Metric | FY2022 | FY2021 | Change |
|---|---|---|---|
| Total revenue | $9.975 million | $10.217 million | Down 2% |
| Gross profit / margin | $4.731 million / 47% | $5.633 million / 55% | Margin down 8 percentage points |
| Operating loss, continuing operations | $4.335 million | $3.252 million | Loss increased $1.083 million |
| Net loss, including discontinued operations | $7.106 million | $3.867 million | Loss increased $3.239 million |
| Net loss attributable to Nephros shareholders | $7.382 million | $4.107 million | Loss increased $3.275 million |
| Cash used in operating activities | $3.234 million | $1.417 million | Use increased $1.817 million |
| Cash and cash equivalents at year-end | $3.634 million | $6.973 million | Down $3.339 million |
| Working capital | $6.849 million | $11.244 million | Down $4.395 million |
| Total liabilities | $2.118 million | $2.901 million | Down $0.783 million |
- FY2022 product revenue was $9.929 million; royalty and other revenue was $46,000. Water Filtration revenue fell 2%, while Renal Products revenue remained zero.
- Gross margin declined mainly because of higher shipping costs and inventory reserves for expirations, obsolescence, and inventory-count adjustments. A broad price increase began June 1, 2022; management reported gross margin of 59% in Q4, within its 55%–60% target range.
- Operating expenses were $9.066 million, up from $8.885 million. SG&A rose 6% to $7.593 million, primarily due to sales hiring, travel, and recruiting; R&D declined 16% to $1.255 million.
- Discontinued PDS operations generated a $2.829 million loss, including a $1.395 million impairment charge. The continuing-operations loss was $4.277 million, versus $2.784 million in 2021; the prior year included $482,000 of PPP loan forgiveness income.
- Year-end secured note principal was $71,000, due in 2023. Lease liabilities totaled approximately $1.021 million, including $309,000 current operating lease liabilities and $12,000 of finance lease liabilities. Equipment financing was approximately $1,000.
- Accounts receivable was $1.286 million and inventory was $3.153 million, down from $1.641 million and $4.462 million, respectively, at year-end 2021. Stockholders’ equity was $8.881 million; accumulated deficit was $142.831 million.
Material developments and outlook
- Liquidity and going concern: Management cited accumulated losses and recurring negative operating cash flows as conditions raising substantial doubt about the company’s ability to continue as a going concern. Management believes available cash and anticipated revenue can fund its current operating plan for at least 12 months from issuance of the financial statements, citing reduced cash burn, expense and headcount reductions, PDS divestiture, price increases, and sales hiring. This is not a guarantee; management says further cuts may be needed if results fall short.
- SRP/HDF: SRP received FDA 510(k) clearance for its second-generation HDF system in May 2022 but could not secure a commercial partner or additional financing. SRP approved a wind-down in March 2023. Nephros does not expect cash repayment of its approximately $1.4 million loan to SRP and anticipates receiving SRP’s remaining assets, including HDF2 intellectual property, in partial satisfaction. Nephros has no current HDF commercialization plan, though it may reassess opportunities.
- PDS divestiture: Nephros sold substantially all PDS assets to BWSI in November 2022, exiting the business. The filing describes $1,000 cash consideration at closing and potential royalties over seven years, subject to a minimum gross-margin threshold; those royalties are contingent and had not been recognized as revenue. The filing’s business discussion separately describes a nominal cash payment, so the exact closing consideration merits verification.
- Medica commitments and supply exposure: Nephros relies on Medica under an exclusive license and supply agreement that runs through December 31, 2025, with a single-source supplier for certain filter materials. Minimum purchases are €3.625 million in 2023, €3.825 million in 2024, and €4.0 million in 2025. The 2022 minimum was €3.5 million; actual purchases were €3.2 million, with the shortfall to be made up based on anticipated future revenues. Unpaid invoices may bear 12% annual interest under the company’s understanding with Medica.
- Commercial opportunity and concentration: In March 2022, Nephros entered a contract to supply filtration systems to an organization of approximately 3,000 quick-service restaurants. The filing provides no quantified revenue outlook for this contract or formal company-wide revenue or earnings guidance. Three customers accounted for 42% of FY2022 revenue, with the largest representing 25%.
- Other risks: Key risks include continued operating losses and financing needs; limited market acceptance and competitive pressure; reliance on third-party manufacturing and suppliers; inflation, freight, and supply-chain costs; product liability and regulatory compliance; customer concentration; and dependence on a small senior-management team. Product liability insurance coverage is $3 million.
- Controls and audit: Management concluded disclosure controls and internal control over financial reporting were effective at year-end. The independent auditor issued an unqualified opinion on the financial statements, identified inventory valuation as a critical audit matter, and did not audit or opine on internal control effectiveness.
Most important facts for investors to verify
- Whether cash, sales, and expense assumptions support management’s stated 12-month liquidity outlook, especially given $3.234 million of FY2022 operating cash use and the going-concern disclosure.
- The cash consideration and final terms of the PDS asset sale, and whether BWSI royalties become payable under the agreement’s thresholds.
- The actual timing and value of SRP assets transferred to Nephros, and the accounting treatment of the approximately $1.4 million SRP loan balance.
- Ability to meet Medica’s minimum purchase commitments, address the 2022 shortfall, and maintain supply at acceptable costs.
- Whether the large QSR contract converts into sustained incremental sales, and whether customer concentration changes.
- Inventory reserve adequacy and gross-margin sustainability after the 2022 price increases and shipping-cost pressures.